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Figure. Signiﬁcant correlation between pulmonary artery pressure and cardiac iron.Ă
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S20Conclusion: All patients with transfusion dependent thalassaemia major
should be screened with a cardiac MRI for iron overload from the age of 7
years as serum ferritin done serially alone does not detect tissue iron
deposition. Aggressive chelation with the addition of deferiprone which
acts synergistically with deferasirox or desferrioxamine must be
commenced to reduce the incidence of cardiomyopathy in these patients
despite a low serum ferritin value. This is the ﬁrst comprehensive study of
cardiac iron in India and we plan to follow up this cohort annually to
evaluate the outcome of the intervention with serial cardiac MRI.
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A PROSPECTIVE OBSERVATIONAL STUDY ON CLINICO-ETIOLOGICAL
PROFILE OF PANCYTOPENIA IN CHILDREN
M. Alim 1, A. Kumar 2, N. Verma 1, V. Pooniya 1. 1Department of Pediatrics,
KGMU, Lucknow, India; 2Department of Pediatric Hemato-Oncology, KGMU,
Lucknow, India
Background: Pancytopenia is a disorder in which all three major formed
elements of blood (red blood cells, white blood cells and platelets) are
decreased in number.Relevance of the study lies in the timely interven-
tion for the causes of pancytopenia which can either bring about a
complete cure or at least a remission from the disease entity. In India not
many studies have been done on this topic especially in pediatric age
group so the present study has been undertaken to evaluate the various
causes of pancytopenia, their clinical proﬁle and outcome.
Methods: This was a prospective observational study of 81 patients aged
between 1 month to 15 years admitted to Department of Pediatrics of King
George Medical University, Lucknow during August 2015 to July 2016 with
Hb<10g/dl, TLC<4000/mm3 and platelets<1 lakh/mm3. Patients under-
going/already undergone chemotherapy and radiotherapy were exclu-
ded.After informed consent, a detailed medical history, physical
examination, complete blood counts, anaemiaworkup, viral markers, bone
marrow examination was done along with transfusion records, treatment
received and outcomes were analysed.
Results: The bulk of patients were from rural background (87%).The mean
age at presentationwas 74months (range 1-180month) withMale:Female
e 2.8:1.
The most common clinical presentations were fever (78%), pallor (67%),
bleeding manifestations (43%); past h/o jaundice (5%) and pesticide
exposure (8%); hepatomegaly (56%) splenomegaly (42%) Lymphadenop-
athy (22%) and knuckle hyperpigmentation (14%).
The haematological parameters showed mean haemoglobin level: 4.9 gm/
dL, WBC: 2676/mm3, ANC: 1009/mm3, platelet: 43700/mm3, MCV:85.5
MCH: 30.5 RDW: 23.5 B12 487.7 Folate 12.3 Ferritin 777 s.Iron 179.8 .PNH
clone was present in 2.1%, Parvo B19 in 6% and EBV in 7% of patients.
5 patients (6%) were lost to follow up or expired before any treatment was
initiated.
Most common causes of pancytopenia found in our study were
Aplastic Anemia (49%), Acute leukemia (27%) and Megaloblastic/Nutritional (18%). Infections (9%) and hypersplenism (6%) etc accounted for
the rest.
All patients with megaloblastic anemia survived despite no trans-
fusions. But patients with very severe Aplastic Anemia and hemato-
logical malignancies had worse outcomes despite ATG courses ;
multiple transfusions and induction chemotherapy respectively.Patient
with Kala Azar, chronic Malaria infections and hypersplenism survived
after appropriate treatment.Also hospital stay was prolonged for leu-
kemias and Aplastic Anemia.
Conclusion: The etiology of pancytopenia varies widely ranging from
transient marrow viral suppression, drugs etc to marrow inﬁltration by
life-threatening malignancy.The severity of pancytopenia and the under-
lying pathology determine the management and prognosis of the patients
.Hence such studies will help in planning the diagnostic and therapeutic
approach in patients with pancytopenia and curtailing delays to reduce
multiple transfusions, pre-treatment infections and overall morbidity and
mortality associated with entity of Pancytopenia.
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ADVERSE DRUG EVENTS WITH IRON CHELATION DRUGS IN
THALASSEMIC PATIENTS ATTENDING A DAY CARE THALASSEMIA
CENTRE IN TERTIARY CARE GOVT. MEDICAL COLLEGE IN NORTH INDIA
Kishore Kumar Digra, Sanjeev Kumar Digra, Rajesh Kaul, Subhash Singh
Slathia. Department of Pediatrics, SMGS Hospital, Government Medical
College, Jammu, India
Introduction: The Last three decades have witnessed profound changes in
the management of patients with thalassemia major. Regular and periodic
blood transfusion being the main stay of treatment results in iron overload
thus necessitating need for iron chelation. At present three iron chelators
namely, Desferrioxamine, Defriprone and deﬁrasirox are in use alone or in
combinations. Since the iron chelators are required to be given for the life-
time they also cause adverse events which are range from trivial to life
threatening.
Aims: To identify and manage adverse drug events due to iron chelating
drugs experienced by thalassemic patients.
Material and methods: This is an observational study done during 1st
January to 30th June 2016 in Thalassemia Day Care Centre of SMGS hospital,
Govt. Medical College Jammu. All the adverse events were recorded on a
pretestedproformaandwerevalidatedonNaranjo causalityassessmentscale.
Results: Of the 280 patients with the age ranging from 6 months to 53
years registered with Thalassemia Day Care Centre SMGS hospital Govt.
Medical College Jammu only 180 attended regular fortnightly follow up
clinics. Out of these 180 patients 168 are on Iron chelation drugs (129 on
Defriprone, 24 on Deﬁrasirox, 8 on Defriprone + Desferrioxamine, 4 on
Desferrioxamine and 3 on Defriprone + Desferrixamin) Out of 32 events
observed during the course of study 21 (65.62%) were due to Defriprone,
8 (25%) due to Deferasirox and 3 (9.38%) due to Desfferioxamine. Out of
21 events due to Defriprone 12 (57.14%) were gastrointestinal symp-
toms, 5 (23.8%) arthropathy, 2 (9.5%) Neutropenia and 2 (9.5%) throm-
bocytopenia. All 8 (100%) events due to Deferasirox were
gastrointestinal symptoms. 2 (66.66%) events with desferrioxamine
were local reactions and 1 (33.33%) was encephalitis. On Naranjo Cas-
uality scale 5/32 was deﬁnite while as 24 /32 was probable and 3/32
were possible. While 9 were mild reactions, 4 were severe reactions and
19 were moderate reactions.
Conclusion: Majority of adverse events were observed with Defriprone
followed byDeferasirox. Although least adverse eventswere observedwith
desferrioxamine, but adverse events with deferasirox were least severe.
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ACQUIRED APLASTIC ANAEMIA IN CHILDREN e OPTIMAL OUTCOMES
DEPEND ON OPTIMAL DELIVERY OF IMMUNOSUPPRESSIVE THERAPY
Dhaarani Jayaraman, Ramya Uppuluri, Divya Subburaj,
Venkateshwaran, Revathi Raj. Department of Paediatric Haematology,
Oncology and Blood and Marrow Transplantation, Apollo Speciality
Hospital, Chennai, India
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S21Background: Acquired aplastic anemia (AA) is a haematological emer-
gency in children and we have gained enormous knowledge about the
pathogenesis and immune mediated self-destruction of stem cells and
immunosuppressive therapy. Due to its rarity, we have limited data of this
entity, especially, its course and outcome in resource limited countries.
Patientsandmethods: The case recordsof childrenwhohadbeendiagnosed
to have AA since 2002 at our centre were reviewed. The diagnosis of AAwas
made in children with pancytopenia without organomegaly and conﬁrmed
by hypocellular bone marrow showing decreased expression of all three
hematopoietic lineages. Clinical ﬁndings including dysmorphism, thumb
abnormalities, congenital malformations and skin hyperpigmentation were
noted down. Mitomycin C induced chromosomal instability to rule out Fan-
coni anaemia, Ham's test to look for paroxysmal nocturnal haemoglobinuria
and chromosomal analysis to look for complex karyotypic abnormalities seen
in myelodysplastic syndrome were documented in all patients.
After initial stabilization, the option of haematopoietic stem cell trans-
plantation (HSCT) was offered to all those who had matched related do-
nors. If not, immunosuppressive therapy was delivered within twomonths
from diagnosis after the child was infection free. A combination of 40mg/
kg/day of Horse derived antithymocyte globulin (ATGAM) and methyl-
prednisolone at 2 mg/kg/day were started for the ﬁrst 4 days through a
central venous catheter. Oral cyclosporine and G-CSF were started on the
ﬁfth day and since 2015 Eltrombopag was added to the IST regimen.
Revolade and GCSF were continued for about 8 to 12 weeks and cyclo-
sporine from 6 to 12 months. All patient received Voriconazole and
Acyclovir prophylaxis till neutrophil recovery to 1000.
Results: A total of 109 children had been diagnosed as AA, of whom, 42
had acquired AA. Themean age of childrenwith acquired AAwas 8.16 years
(2-15 yrs). Boys were twice more commonly affected (ratio M: F ¼ 2:1).
Details are listed in table 1.
Of the 41, 21 underwent HSCT as they had fully matched related donor and
20 children received IST. Of the 20 children who received ATG, 10 children
(70%) had complete remission in a median duration of 78 days. Two of the
three non responders were treated with second IST and all three succumbed
to the illness. One child developed acute myeloid leukaemia after achieving
partial remission and was salvaged with HSCT, and 1 more non responder
had an unrelated HSCT and is doing well. One child has suffered a relapse
after a durable remission of over 18 months off immunosuppression. The 21
children who have been transplanted have an overall survival rate of 77 %.
Conclusion: Immunosuppressive regimen including Horse ATGAM,
Methyl prednisolone, Cyclosporine, GCSF and Eltrombopag along with
adequate and meticulous supportive care including neutropenic care,
prompt infection management and the use of irradiated and leukode-
pleted blood products results in a 70% response rate and should be offered
to all children with aplastic anaemia with no matched family donor. The
addition of Elthrombopag has resulted in early recovery of all three cell
lines and must be added to the IST protocol in children.Table 1
Clinical features & treatment outcome in Pediatric Aplastic anemia, n¼41
S. No Parameter Results
1. Mean age at presentation 8.16 year
2. Severity at presentation
Severe 41%
Very severe 54%




Partial trisomy 10,14 & Trisomy 7 1
Mitomycin-C rest Equivocal in 1
Negative in others
Ham's test Negative in all
5. Treatment
1. ATG group 20
Survival 16
Complete Response 14
Second IST 2 (expired)
Salvage BMT 2
2. BMT group 21
Survival 16
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IS SERUM FERRITIN A RELIABLE MARKER FOR EVALUATION OF
CARDIAC AND HEPATIC IRON OVERLOAD IN PATIENTS WITH b-
THALASSEMIA MAJOR?
Ankita Pandey, Arijita Chatterjee, Reshma Nevgi, Amit Jain, Prakruthi
Kaushik, Sujata Sharma, Ratna Sharma, Mamta Manglani.
Background: Regular packed red cell transfusions, which is the mainstay
of therapy in thalassemia major, leads to iron overload. This requires
frequent monitoring, thereby instituting appropriate treatment and pre-
venting its associated complications. Iron overload-induced cardiomyop-
athy is reversible if intensive chelation therapy is instituted on time. Early
detection of myocardial iron deposition is imperative to prevent cardiac
complications known with iron overload. Conventionally, serum ferritin
has been used to monitor iron overload in these children. But there have
been recent studies, which have shown that T2* MRI is a better tool for
cardiac and liver iron overload in comparison with serum ferritin. We
analyzed our data to verify this correlation in our patients.
Aims and objectives: To study the correlation between serum ferritin and
T2*MRI for assessment of cardiac and hepatic iron overload in patients of
b-Thalassemia Major.
Materials andmethods: It was a retrospective, cross sectional, descriptive
study which analyzed records of 52patients with transfusion dependent b-
Thalassemia major in the Thalassemia day care centre at our institution.
Inclusion Criteria: Children with transfusion dependent b-thalassemia
major above 6 years of age in whomserum ferritin and T2*MRI were per-
formed at least within 3 months of each other.
Exclusion criteria: Any child withHepatitis B, Hepatitis C and HIV
infection.
Methodology: Demographic data, serum ferritin during last 3 months and
T2*MRI results (which was taken as the gold standard for iron overload)
were retrieved from the records.Standard deﬁnitions of severity of iron
overload for liver and heart on T2* MRI were used for comparisons (Liver:
normal > 6.3ms, mild - 2.8-6.3ms, moderate - 1.4-2.7ms, severe <1.4ms,
Cardiac: normal >20ms, mild - 14 e 20ms, moderate - 10 e 14ms, severe
<10ms.).Statistical analysis was done using Fisher's Exact test and ANOVA
test.
Results: A total of 52 patients were enrolled in the study.Their ages
ranged from 6 years to 22, with a median of 8.5yrs .31 were males and 21
were females. On the basis of T2* MRI values, patients were divided into
none, mild, moderate and severe hepatic and cardiac iron overload. He-
patic iron overload in our patients was as follows: none e 5 (9.6%), mild e
14 (26.9%), moderate e 10 (19.2%), severe e 23 (44.2%) and cardiac iron
overload as follows: none e 36 (69.2%), mild e 12 (23.0%), moderate e 3
(5.7%), severe e 1 (1.9%). When correlating serum ferritin below and
above 2000 ng/ml with the severity of iron overload on T2*MRI, therewas
no signiﬁcant association between serum ferritin levels and degree of iron
overload in cardiac as well as liver MRI (p ¼ 0.92 for cardiac iron overload
and p ¼ 0.39 for liver iron overload).Our results also show that there was
no signiﬁcant correlation between serum ferritin and cardiac MRIﬁndings
(p ¼ 0.725) or between ferritin and hepatic MRI (p ¼ 0.910). Also no
signiﬁcant correlation was observed between cardiac and hepatic MRI
values (p ¼ 0.07).
Conclusion: The present study concludes that there is no correlation be-
tween serum ferritin level and T2*MRI for cardiac as well as liver iron
overload. Hence, serum ferritin should not be the sole marker for evalu-
ating iron overload. Also, cardiac and hepatic iron overload on T2* MRI did
not correlate with each other. This suggests that individual organ evalua-
tion by T2* MRI may be the way ahead for effective prevention of com-
plications by appropriate chelation.
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RIC HSCT IN PRIMARY IMMUNODEFICIENCY CHILDREN IN DEVELOPING
WORLD e A RAY OF HOPE
Neha Rastogi, Dhwanee Thakkar, Shruti Kohli, Sagar Nivargi, Satyendra
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